Breaking News

Tweet TWEET

Stock Price Movements, Completion of Acquisitions, and Clinical Trial Initiations - Research Report on Endocyte, PharMerica,

    Stock Price Movements, Completion of Acquisitions, and Clinical Trial
 Initiations - Research Report on Endocyte, PharMerica, Synta, AtriCure, and
                                 Cytokinetics

PR Newswire

NEW YORK, January 15, 2014

NEW YORK, January 15, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Endocyte,
Inc. (NASDAQ: ECYT), PharMerica Corporation (NYSE: PMC), Synta Pharmaceuticals
Corp. (NASDAQ: SNTA), AtriCure, Inc. (NASDAQ: ATRC), and Cytokinetics,
Incorporated (NASDAQ: CYTK). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Endocyte, Inc. Research Report

On January 10, 2014, Endocyte, Inc.'s (Endocyte) stock ended the day at
$14.02, compared to the previous closing price at $10.90, representing a
significant 28.62% growth. The Company's stock grew 28.04% over the past three
trading days, compared to the Dow Jones Industrial Average Index which
declined 0.57% during the same period. The Full Research Report on Endocyte,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/fdf5_ECYT

--

PharMerica Corporation Research Report

On January 10, 2014, PharMerica Corp. (PharMerica) announced that it has
completed acquisition of BGS Pharmacy Partners Inc. (BGS) in an all-cash
transaction. Greg Weishar, PharMerica's CEO, stated, "The transaction
increases our presence in two important markets where we have existing
operations, Las Vegas and Salt Lake City, and expands our geographic footprint
in the Reno area. BGS has a talented team and has built a strong business
based on patient care, clinical expertise, and customer service. We look
forward to working with BGS' outstanding client base to serve the needs of
their residents." The Company informed that it expects the acquisition to be
accretive to its earnings in 2014. The Full Research Report on PharMerica
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/b04b_PMC

--

Synta Pharmaceuticals Corp. Research Report 

On January 9, 2014, Synta Pharmaceuticals Corp. (Synta) announced the
initiation of three multicenter, randomized Phase II/III Trials, evaluating
ganetespib in combination with chemotherapy in first-line treatment of
patients with AML and high risk MDS. According to the Company, preclinical
results from Synta and its collaborators, Alan K. Burnett of Cardiff
University and Sanjay Bansal of the UT Health Science Center at San Antonio,
have shown that ganetespib inhibits a number of cancer-promoting factors
believed to contribute to the proliferation of leukemic cells and renders them
more vulnerable to treatment with chemotherapy. "The selection of ganetespib
for three major potentially registration-enabling trials in AML is an exciting
validation of the clinical potential of ganetespib, and reinforces our
strategy of continuing to expand the depth and breadth of the ganetespib
program through collaborations with strong groups of investigators," said Safi
R. Bahcall, Ph.D., President and CEO of Synta. "Promising preclinical and
early clinical results have been observed with ganetespib and other Hsp90
inhibitors in AML. We are pleased by the decision of the Leukemia & Lymphoma
Research Fund, the Cancer Research UK, and the trial investigators to invest
in moving ganetespib forward into three large, randomized trials, which we
hope will ultimately lead to new options for patients with this devastating
disease." The Full Research Report on Synta Pharmaceuticals Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/8ecc_SNTA

--

AtriCure, Inc. Research Report

On January 2, 2014, AtriCure, Inc. (AtriCure) announced the completion of the
previously announced acquisition of Endoscopic Technologies, Inc. (Estech).
Mike Carrel, President and CEO of AtriCure, said, "We are pleased to complete
the acquisition of Estech, and we welcome the team to AtriCure. This
transaction provides substantial benefits to AtriCure and strengthens our
leadership position in the atrial fibrillation market; we are excited about
the opportunities that our combined businesses will bring to our customers."
AtriCure informed that it expects the transaction to increase sales and
marketing expense as well as research and development expenditures in order to
accelerate clinical development and commercial sales of the combined product
portfolio. AtriCure further expects the transaction to be dilutive to earnings
in 2014 and accretive in 2015 and beyond. The Full Research Report on
AtriCure, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at: 

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/f01d_ATRC

--

Cytokinetics, Incorporated Research Report  

On January 10, 2014, Cytokinetics, Inc.'s (Cytokinetics) stock ended the day
at $9.58, compared to the previous closing price at $8.35, representing a
14.73% growth. The Company's stock grew 22.51% over the past three trading
days, compared to the Dow Jones Industrial Average Index which declined 0.57%
over the same trading period. The Full Research Report on Cytokinetics,
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5338_CYTK

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.